

**Question for written answer E-002450/2021  
to the Commission**

Rule 138

**Joanna Kopcińska** (ECR)

Subject:     Updating of EU industrial strategy

On 5 May this year, the Commission presented an update of the action of the EU industrial strategy aimed at adapting industry to the new circumstances arising from the COVID-19 crisis. The Commission presented a bottom-up analysis based on commercial data, noting that the EU health ecosystems (including the issue of active pharmaceutical ingredients) are highly dependent on external, non-EU suppliers.

1. In the context of updating the actions of the EU industrial strategy and the resolution entitled 'Shortage of medicines – how to address an emerging problem', adopted by Parliament on 17 September 2020, I would like to ask which specific legal and financial instruments the Commission plans to use to actually support Member States' efforts to pool public resources via Important Projects of Common European Interest (IPCEIs) in areas where the market alone cannot ensure sufficient independence (as regards active pharmaceutical ingredients)?
2. During the current COVID-19 pandemic, which is having an additional impact on the shortages of medicines used, for example, in the treatment of cancer, and as part of the updated actions of the EU industrial strategy, does the Commission plan to carry out an additional 'bottom-up' analysis based on commercial data to identify which types and groups of medicines are affected by the problem relating to vulnerable health ecosystems and exacerbating strategic dependency?